HeartCore Enterprises Files 8-K
Ticker: HTCR · Form: 8-K · Filed: Mar 18, 2024 · CIK: 1892322
| Field | Detail |
|---|---|
| Company | Heartcore Enterprises, Inc. (HTCR) |
| Form Type | 8-K |
| Filed Date | Mar 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $500,000, $300,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, reporting
TL;DR
HeartCore filed a routine 8-K, no major news.
AI Summary
HeartCore Enterprises, Inc. filed an 8-K on March 18, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates that HeartCore Enterprises, Inc. is fulfilling its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting purposes and does not disclose any new material information that would inherently increase risk.
Key Players & Entities
- HeartCore Enterprises, Inc. (company) — Registrant
- March 18, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for HeartCore Enterprises, Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and Financial Statements and Exhibits, as indicated in the filing.
On what date was this 8-K report filed or effective?
The report was filed as of March 18, 2024, and the date of the earliest event reported is also March 18, 2024.
What is the state of incorporation for HeartCore Enterprises, Inc.?
HeartCore Enterprises, Inc. is incorporated in Delaware.
What is the principal executive office address for HeartCore Enterprises, Inc.?
The principal executive offices are located at 1-2-33, Higashigotanda, Shinagawa-ku, Tokyo, Japan.
Does this 8-K filing disclose any specific financial results or material events?
Based on the provided text, this 8-K filing does not disclose specific financial results or new material events; it primarily serves as a reporting document.
Filing Stats: 593 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-03-18 16:55:13
Key Financial Figures
- $500,000 — generate from PharmaBio an aggregate of $500,000 in initial fees and $300,000 in success
- $300,000 — gregate of $500,000 in initial fees and $300,000 in success fees. In addition, the Compa
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001493152-24-010333.txt ( ) — 239KB
- htcr-20240318.xsd (EX-101.SCH) — 3KB
- htcr-20240318_lab.xml (EX-101.LAB) — 33KB
- htcr-20240318_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HEARTCORE ENTERPRISES, INC. Dated: March 18, 2024 By: /s/ Sumitaka Yamamoto Name: Sumitaka Yamamoto Title: Chief Executive Officer